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Background: Circulating endothelial progenitor cells (EPCs) may be a biomarker for vascular function and
cardiovascular risk in patients with coronary artery disease (CAD). Dimethylarginine dimethylaminohydrolase 2
(DDAH2) regulates the function of EPCs. This study aimed to examine whether hypermethylation of DDAH2
promoter contributes to impaired function of EPCs in CAD patients.
Methods: Peripheral blood mono-nuclear cells from 25 CAD patients and 15 healthy volunteers were collected and
differentiated into EPCs. EPCs were tested for their adhesive capability. DDAH2 mRNA expression was analyzed by
real-time PCR, and the methylation of DDAH2 promoter was detected by bisulfite genomic sequencing.
Results: DDAH2 promoter in EPCs from CAD patients was hypermethylated and the methylation level was
negatively correlated to DDAH2 mRNA level and adhesion function of EPCs. Homocysteine impaired the adhesion
function of EPCs, accompanied by lower DDAH2 expression and higher methylation level of DDAH2 promoter,
compared to controls. These effects of homocysteine were reversed by pretreatment with Aza, an inhibitor of DNA
methyltransferase.
Conclusion: Hypermethylation in DDAH2 promoter is positively correlated to the dysfunction of EPCs in CAD
patients. Homocysteine disrupts EPCs function via inducing the hypermethylation of DDAH2 promoter, suggesting
a key role of epigenetic mechanism in the progression of atherosclerosis.
Keywords: Endothelial progenitor cells, Atherosclerosis, DNA methylation, Dimethylarginine
dimethylaminohydrolase, HomocysteineIntroduction
Both clinical research and animal experiments have
demonstrated that endothelial repair/regeneration de-
pends on the availability of circulating endothelial pro-
genitor cells (EPCs), and EPCs function is disrupted by
cardiovascular diseases, such as hypertension, hyperchol-
esterolemia and coronary artery disease (CAD), as well
as by other diseases such as diabetes mellitus [1-3].
Absence of sufficient circulating EPCs may in turn affect
the progression of cardiovascular diseases [4]. Clinical
trials conducted in CAD patients demonstrated that the
level of circulating EPCs may be a surrogate biologic* Correspondence: zhbk@126.com; sujiejia@yeah.net
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cular risk [4]. Furthermore, the level of circulating EPCs
may predict the occurrence of cardiovascular events and
death from cardiovascular causes which may help iden-
tify patients at increased cardiovascular risk [4-6].
Increased level of circulating asymmetric dimethylargi-
nine (ADMA), an endogenous nitric oxide synthase (NOS)
inhibitor, has been implicated in endothelial dysfunction
in atherosclerosis [7]. Two isoforms of dimethylarginine
dimethylaminohydrolase (DDAH) are responsible for the
metabolization of ADMA. DDAH2 predominates in tissues
that express endothelial NOS and the impairment of
DDAH2 activity and/or expression rather than DDAH1 ap-
pears to be responsible for the elevation of plasma ADMA
in endothelial cells of atherosclerosis [8]. Consequently,
DDAH2 is recognized as a protective factor of endothelial. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lar diseases such as atherosclerosis, diabetes mellitus and
aging [9].
Elevated homocysteine (Hcy) has been regarded as an
independent risk factor for atherothrombotic vascular
diseases [10]. Hcy reduces the number and function of
EPCs which may be due to accelerated senescence of
EPCs [11]. Our previous study has shown that hyperme-
thylation of DDAH2 gene contributes to hcy-induced
apoptosis of endothelial cells, which could be inhibited
by epigallocatechin-3-gallate [12,13]. In this study we
aimed to explore the possible involvement of aberrant
methylation of DDAH2 promoter in the modulation of
EPCs in CAD patients and determine whether the ef-
fects of Hcy on EPCs cells are mediated by the induction
of DDAH2 promoter methylation.Materials and methods
Study population
Twenty-five CAD positive patients (at least one coron-
ary artery stenosis >50%) and 15 negative patients
(angiographically normal) were randomly recruited
from the Third Xiangya Hospital of Central South
University. The characteristics of the patients were
shown in Table 1. This study was approved by Ethics
Committee of the Third Xiangya Hospital of Central
South University, and written informed consent was
obtained from all subjects.Table 1 General characteristics of the patients and
controls
Control CAD patients P
(n = 15) (n = 25)
Gender 0.7360
Male (%) 10 (67.70) 18 (72.00)
Female (%) 5 (32.30) 7 (28.00)
Age (years) 64.73 ± 3.00 67.36 ± 2.00 0.3469
BMI, kg/m2 23.10 ± 0.43 22.53 ± 0.37 0.3289
SBP, mm Hg 160.70 ± 4.00 161.00 ± 4.00 0.9438
DBP, mm Hg 91.40 ± 3.00 92.80 ± 3.00 0.8707
Creatinine, μmol/L 84.41 ± 6.17 109.6 ± 22.25 0.3943
Homocysteine, μmol/L 10.9400 ± .73 16.3400 ± 1.47 0.004
fasting blood-glucose (mmol/L) 7.06 ± 0.78 6.03 ± 0.40 0.1131
Triglyceride, ìmol/L 2.45 ± 0.48 1.97 ± 0.24 0.3320
Total cholesterol, ìmol/L 4.49 ± 0.24 4.53 ± 0.20 0.8967
LDL-C, mmol/L 2.65 ± 0.31 2.80 ± 0.43 0.8966
Positive history of diabetes (%) 5(40) 4(16) 0.2550
Positive history of smoking (%) 3(20) 9(36) 0.4770
Positive history of drinking (%) 3(20) 11(44) 0.1770Cell culture
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from the blood of both CAD patients and volun-
teers by density gradient centrifugation with Histopaque
1077 (Sigma-Aldrich, St Louis, Missouri, USA). PBMCs
were resuspended in six-well plates coated with human
fibronectin (Chemicon, Temecula, CA, USA), and cul-
tured in endothelial basal medium-2 (EBM-2) (Clonetics,
Walkersville, MD, USA) supplemented with endothelial
growth medium-2 (EGM-2). The medium was changed
every 3 days of culture.
Flow cytometry
EPCs were cultured for 14days, then incubated with
6 μg/mL 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbo-
cyanine-labeled acetylated low-density lipoprotein (acLDL-
DiI) at 37°C for 2 h, and then with 10 μg/mL FITC-labeled
Ulex europaeus agglutinin-1 (UEA-1) for 1 h. To detect the
markers, flow cytometry was performed following routine
procedures with the following primary antibodies: PE-
conjugated mouse anti-CD133 antibody (1:400 dilution),
PE-conjugated mouse anti-CD34 antibody (1:400 dilution),
Alexa Fluor® 488-conjugated mouse anti-CD45 (1:400
dilution), and Alexa Fluor® 647 mouse monoclonal
anti-VEGFR-2 antibodies (1:400 dilution). All these anti-
bodies were from Biolegend (San Diego, CA, USA). Normal
mouse, goat and rabbit IgGs were substituted for primary
antibodies as negative or isotype control. After final washes
in PBS, all the samples were analyzed by fluorescence-
activated cell sorting (FACS) FACScalibur system (Becton
Dickinson, San Diego, CA) (gating strategy for FACS was
shown in Additional file 1: Figure S1), and observed in an
inverted fluorescent microscope (Nikon, Japan).
Detection of adhesion ability of EPCs
EPCs were cultured for 14 days and collected by diges-
tion with 0.25% trypsin and centrifugation. Then the
cells were resuspended in EGM-2 medium at the density
of 1 × 105/ml. 200 μl cell suspension was seeded in 24-
well plates coated with HFN and incubated at 37°C for
2 h. Next the non-adherent cells were washed away and
the adherent cells were incubated with Hoechest33342
staining solution at 37°C for 20 min, followed by wash-
ing with PBS twice. Finally, the stained nuclei were
observed and counted under an inverted fluorescence
microscope.
Real-time quantitative PCR
Total RNA was isolated from EPCs using the RNeasy
mini kit (Qiagen, Valencia, CA, USA). Real-time quantita-
tive RT-PCR was performed using a Rotor-Gene 3000
(Corbett Research, Mortlake, NSW, Australia) and mRNA
levels were quantified using the One Step PrimeScript
RT-PCR Kit (TaKaRa, Dalian, China). The primers were as
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TGA-3′and reverse 5′-CTAGATCTCTAGGTCATCAGG
CCG-3′; GAPDH forward 5′-AACAGCCTCAAGAT
CATCAG-3′ and reverse 5′-GGATGATGTCTGGA
GAGCC-3′.
Detection of DNA methylation
Genomic DNA was extracted from cells with TIANamp
Genomic DNA kit and the purity of the extracted DNA
was judged based on A260/A280 ratio. Genomic DNA
was subjected to sodium bisulfite modification by using
EpiTect bisulfite kit, and nested PCR was carried out
with GoTaq hot star polymerase system (Promega, WI,
USA). The primers were as follows: outer pairs GTAG
GGAATTTTGGAGTATTTGTTT and CTAAAAAATT
AAACATCCTCTCTCC, product size: 1,013 bp, CpGs
in product: 65; inner pairs GGTGGGTTAGTGATTTT
GAGTTTAG and CTCCCCATACTCTCTATCTAATA
CAAAC, product size: 587 bp, CpGs in product: 43.
PCR products were purified by gel electrophoresis, and
subcloned into pGEM®-TEasy Vector System (Promega,
WI, USA) for sequencing by Beijing Genomics Institute
(Beijing, China).
Statistical analysis
Data were expressed as mean ± standard deviation
( x  SD ). Multiple samples were compared by using
one-way ANOVA, pairwise comparison was performed
by LSD method. Spearman correlation coefficient was
calculated by bivariate correlation analysis. All analyses
were performed with SPSS 13.0 software. P < 0.05 was
considered significant.
Results
Phenotypic characterization of EPCs
EPCs were isolated from PBMCs of all the subjects.
EPCs on the 7th day of culture were dominantly of spin-
dle morphology and formed colony on the 14th day of
culture (Figure 1A). EPCs exhibited previously defined
characteristics such as acLDL incorporation and lectin
binding (Figure 1B). In addition, they expressed stem
cell markers CD34 (percentage: 60.3 ± 10.8%), CD45
(percentage: 95.7 ± 10.8%) and CD133 (percentage: 7.5 ±
1.6%), and endothelial cell marker VEGFR-2 (percentage
55.72 ± 14.6%) (Figure 1C).
EPCs from CAD patients exhibit reduced adhesion ability
The adhesion ability of EPCs has been evaluated by the
number of stained nuclei of adherent EPCs [14,15]. To
examine the adhesion ability of clinically isolated EPCs, we
performed Hoechest33342 staining. The results showed
that the adhesion ability of EPCs from CAD patients was
significantly lower than that of EPCs from control group
(143.0 ± 10.8% vs. 107.2 ± 8.7%, P < 0.05) (Figure 2).DDAH2 gene promoter is hypermethylated in EPCs from
CAD patients
Next we detected the methylation status of CpG sites in
the promoter of DDAH2 gene. The mean methylation
status for each of the 12 CpG sites within DDAH2
promoter in EPCs from controls and CAD patients was
shown in Figure 3A and B, respectively. We found that
the average methylation status of DDAH2 promoter
was significantly higher in CAD patients than in
controls (P < 0.05, Figure 3C).
Consistent with the hypermethylation of DDAH2
promoter in EPCs from CAD patients, real-time PCR
analysis showed that DDAH2 mRNA level in EPCs from
CAD patients was markedly reduced compared with
controls (P < 0.01, Figure 3D).
The adhesion ability of EPCs is negatively correlated with
DDAH2 methylation
Many risk factors were reported to contribute to im-
paired dysfunction of EPCs in CAD. Therefore, we ex-
plored whether aberrant DNA methylation of DDAH2 is
involved in this process. Bivariate correlation analysis
was performed for the adhesion function of EPCs and
DDAH2 promoter methylation in 18 CAD patients.
The results showed that the adhesion function of EPCs was
negatively correlated with DDAH2 promoter methylation
level in CAD patients (Pearson’s r = −0.730, P = 0.001,
Figure 4).
Hcy induces the hypermethylation of DDAH2 promoter
in EPCs
We treated EPCs from healthy volunteers with 1 mM
Hcy or the combination of 1 mM Hcy and 5 μM 5-Aza
(the inhibitor of DNA methyltransferase, DNMT). The
mean methylation status for each of the 12 CpG sites
within DDAH2 promoter in EPCs untreated, treated
with 1 mM Hcy, and treated with 1 mM Hcy and 5 μM
5-Aza was shown in Figure 5A,B, and C, respectively.
The results showed that the average methylation status
of DDAH2 promoter was significantly higher in EPCs
treated with Hcy, but 5-Aza abrogated Hcy-induced
hypermethylation of DDAH2 promoter.
Consistent with the effects of Hcy and 5-Aza on the
rmethylation of DDAH2 promoter in EPCs, real-time
PCR analysis showed that Hcy decreased mRNA level
of DDAH2 in EPCs from healthy volunteers in a dose
dependent manner, but 5-Aza could recover mRNA
expression of DDAH2 in EPCs (P < 0.05, Figure 5D).
Hcy decreases the adhesion ability of EPCs
Finally, to determine the biological significance of Hcy-
induced hypermethylation of DDAH2 promoter, we
detected the adhesion ability of EPCs untreated, treated
with 1 mM Hcy and treated with 1 mM Hcy and 5 μM
Figure 1 Characterization of isolated EPCs. A. Representative images of cultured EPCs on 7th day, 14th day, and 20th day (magnification
200×). B. Double-color fluorescent imaging indicated Dil-acetylated LDL incorporation and FITC lectin binding by EPCs. The nuclei was
stained by DAPI (magnification 200×). C. FACS showed the expression of stem cell marker CD45, VEGFR-2, CD34, and CD133 in EPCs at
14th day.
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Figure 6A. Quantitative analysis showed that the adhe-
sion ability of EPCs was inhibited by Hcy, but this could
be abrogated by 5-Aza (Figure 6B).
Discussion
In the present study, we demonstrated that the adhe-
sion function of EPCs was significantly impaired in
CAD patients, accompanied by downregulated expres-
sion of DDAH2. Meanwhile, DDAH2 promoter was
hypermethylated and this was negatively correlated with
the adhesion function of EPCs from CAD patients.Furthermore, we isolated EPCs from healthy volunteers
and treated them with Hcy. The results showed that
Hcy decreased adhesion ability of EPCs, accompanied
by downregulated expression of DDAH and aberrant
hypermethylation of DDAH2 promoter. All these ef-
fects of Hcy were inhibited by 5-Aza, an inhibitor of
DNMT. Taken together, these data suggest that aber-
rant hypermethylation of DDAH2 promoter may play a
role in impairing the function of EPCs and contribute
to CAD.
To date, no consensus has been achieved on the def-
inition of EPCs. The CD34 + CD133 + KDR + cells are
Figure 2 The adhesion ability of EPCs is lower in CAD patients than in controls. A. EPCs were isolated from CAD patients and controls
and cultured for 14 days. A. Representative images of nuclear staining of adherent EPCs. B. Quantitative analysis of the number of adherent
EPCs. *P < 0.05 vs. control group.
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analysis of three markers of EPCs (CD34+, CD133+
and KDR+) has been used for EPCs enumeration [16].
Therefore, in this study we chose the combination of
these three markers to detect EPC populations.
One recent study showed that plaque regression was aug-
mented by adoptive transfer of EPCs in the atherosclerosis-
prone mouse model [17]. However, the bioavailability of
EPCs is affected by endogenous and exogenous risk factors
of atherosclerosis [18]. Exposure to ambient fine particulate
matter air pollution increased the risk for cardiovascular
diseases by preventing EPCs mobilization to peripheral
blood [19]. Hypercholesterolemia also indirectly reduced
both the availability and functionality of EPCs, thus limiting
EPCs-mediated vascular repair [20]. In addition, functional
impairment of EPCs results in severely reduced angiogenic
capacity in vivo in metabolic syndrome [21]. Consistent
with these reports, in the present study we provided
clinical evidence that the adhesion ability of EPCs was
significantly lower in CAD patients compared with
non-CAD volunteers.
In CAD patients, it has been confirmed that ADMA
is an endogenous inhibitor of the differentiation andfunction of EPCs [9]. DDAH2 is an endogenous cata-
bolic enzyme of ADMA, and is expressed at relatively
high level in all fetal tissues [22]. Furthermore, recent
studies revealed the association between DDAH2 gene
polymorphisms and CAD, type 2 diabetes and hypertension
[23,24]. In our present study, we found that DDAH2
mRNA expression was downregulated in EPCs isolated
from CAD patients compared with non-CAD group, sug-
gesting that the downregulation of DDAH2 expression may
contribute to impaired function of EPCs. However, the
mechanism responsible for downregulated expression of
DDAH2 is unclear.
DNA methylation is an important cellular mechanism
that modulates gene expression associated with aging,
inflammation and atherosclerotic processes. Alterations
in DNA methylation profiles, including both hyper- and
hypo-methylation, were present in aortas and PBMCs
without detectable atherosclerotic lesion in 4-week-old
mutant mice [25]. Hypermethylation of DDAH2 contrib-
utes to Hcy induced apoptosis of endothelial cells, which
can be inhibited by epigallocatechin-3-gallate [12,13].
Therefore, modulating DNA methylation status of
DDAH2 promoter may be a potential strategy for the
Figure 4 The adhesion ability of EPCs is negatively correlated with DDAH2 promoter methylation level in CAD patients (r = 0.730,
P = 0.001).
Figure 3 Hypermethylation of DDAH2 promoter and reduced DDAH2 expression in EPCs from CAD patients. A. The mean methylation
status for each of the 12 CpG sites within DDAH2 promoter in EPCs from controls (n = 10). B. The mean methylation status for each of the 12
CpG sites within DDAH2 promoter in EPCs from CAD patients (n = 10). 1 represented fully methylated, 0 represented completely demethylated. C.
The combined average methylation status of 7 CG pairs (positions +3144, +3162, +3170, +3200, +3229, +3261, and +3265) in DDAH2 intron 4 in
EPCs was higher in CAD patients than in controls. *P < 0.05 vs. control group. D. The mRNA expression level of DDAH2 was lower in EPCs from
CAD patients. **P < 0.01 vs. control group.
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Figure 5 Hcy induces the hypermethylation of DDAH2 promoter in EPCs. A. The mean methylation status for each of the 12 CpG sites
within DDAH2 promoter in EPCs untreated. B. The mean methylation status for each of the 12 CpG sites within DDAH2 promoter in EPCs treated
with 1 mM Hcy. C. The mean methylation status for each of the 12 CpG sites within DDAH2 promoter in EPCs treated with 1 mM Hcy and 5 μM
5-Aza. D. Relative mRNA expression of DDAH2 in EPCs of different groups. Values were expressed as means ± SD (n = 3). *P < 0.05, **P < 0.01 vs.
Control; #P < 0.05 vs. 1 mM Hcy treated group.
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demonstrated that DDAH2 promoter was hypermethy-
lated in CAD patients, which may contribute to the
downregulation of DDAH2 expression. Furthermore,
the methylation level of DDAH2 was negatively corre-
lated with adhesion ability of EPCs.
It has been demonstrated that Hcy level is a significant
predictor of mortality, independent of traditional risk
factors [26,27]. Hcy level was higher in CAD patients
than in non-CAD and was inversely correlated with
EPCs’ migratory capacity and ability to adhere to fibro-
nectin [28]. In vitro, Hcy reduced the number of EPCs
via the induction of apoptosis accompanied by decreased
functional activity, which could be reversed by atrovasta-
tin [29]. In this study, we found that plasma level of Hcy
was higher in CAD patients than in controls, which was
consistent with previous reports [30,31]. It will be inter-
esting to elucidate the underlying mechanisms respon-
sible for possible relationship between Hcy level andEPCs. Based on the results from CAD patients, we spec-
ulated that the effects of Hcy on EPCs may be mediated
by the induction of methylation in DDAH2 promoter.
We isolated EPCs from healthy volunteers and treated
them with different concentrations of Hcy. We found
that Hcy decreased the mRNA expression of DDAH2 in
a dose dependent manner in EPCs, which can be inhib-
ited by 5-Aza, the inhibitor of DNMT. Meanwhile, Hcy
impaired the adhesion ability of EPCs and induced aber-
rant hypermethylation in DDAH2 promoter of EPCs.
The effects of Hcy were attenuated by 5-Aza. Unfortu-
nately, several limitations of this study should be pointed
out. First, all these observations are based on cell culture
system and may not reflect human condition. Therefore,
further in vivo studies are needed to confirm our
in vitro results. Second, our analysis of EPCs function
focused only on the adhesion ability. Additional exper-
iments to evaluate the effects of aberrant DDAH2
methylation on the migration and tube formation of
Figure 6 Hcy decreases the adhesion ability of EPCs. A. Representative images of nuclear staining of adherent EPCs in control, 1 mM Hcy
treated, and 1 mM Hcy plus 5 μM 5-Aza treated groups. B. Quantitative analysis of the number of adherent EPCs in each group. *P < 0.05 vs.
control group; #P < 0.05 vs.1 mM Hcy treated group.
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DDAH2 promoter hypermethylation.
Conclusions
In summary, our data provide evidence that aberrant
hypermethylation in DDAH2 promoter is positively
related to the dysfunction of EPCs in CAD patients.
Furthermore, Hcy impaired adhesion ability of EPCs
and induced aberrant hypermethylation in DDAH2
promoter of EPCs, which were attenuated by 5-Aza.
The present study provides new evidence for the role of
aberrant DDAH2 methylation in modulating EPCs function
and suggests a new epigenetic target in the treatment of
atherosclerosis.Additional file
Additional file 1: Figure S1. The gating strategy for FACS analysis of
the markers of EPCs. A. FITC staining. B. PE staining.
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